BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 33767067)

  • 1. Comparison of Immunohistochemical Expression of Cytokeratin 19, c-KIT, BerEP4, GATA3, and NUTM1 Between Porocarcinoma and Squamous Cell Carcinoma.
    Goto K; Ishikawa M; Hamada K; Muramatsu K; Naka M; Honma K; Sugino T
    Am J Dermatopathol; 2021 Nov; 43(11):781-787. PubMed ID: 33767067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD117 (KIT) is a useful immunohistochemical marker for differentiating porocarcinoma from squamous cell carcinoma.
    Goto K; Takai T; Fukumoto T; Anan T; Kimura T; Ansai S; Oshitani Y; Murata Y; Sakuma T; Hirose T
    J Cutan Pathol; 2016 Mar; 43(3):219-26. PubMed ID: 26449497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An immunohistochemical comparison of cytokeratin 7, cytokeratin 15, cytokeratin 19, CAM 5.2, carcinoembryonic antigen, and nestin in differentiating porocarcinoma from squamous cell carcinoma.
    Mahalingam M; Richards JE; Selim MA; Muzikansky A; Hoang MP
    Hum Pathol; 2012 Aug; 43(8):1265-72. PubMed ID: 22285043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engrailed Homeobox 1 and Cytokeratin 19 Are Independent Diagnostic Markers of Eccrine Porocarcinoma and Distinguish It From Squamous Cell Carcinoma.
    Miura K; Akashi T; Namiki T; Hishima T; Bae Y; Sakurai U; Murano K; Shiraishi J; Warabi M; Tanizawa T; Tanaka M; Bhunchet E; Kumagai J; Ayabe S; Sekiya T; Ando N; Shintaku H; Kinowaki Y; Tomii S; Kirimura S; Kayamori K; Yamamoto K; Ito T; Eishi Y
    Am J Clin Pathol; 2020 Sep; 154(4):499-509. PubMed ID: 32556098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of YAP1 and NUT immunohistochemistry in the diagnosis of porocarcinoma.
    Russell-Goldman E; Hornick JL; Hanna J
    J Cutan Pathol; 2021 Mar; 48(3):403-410. PubMed ID: 33222286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NUT Is a Specific Immunohistochemical Marker for the Diagnosis of YAP1-NUTM1-rearranged Cutaneous Poroid Neoplasms.
    Macagno N; Kervarrec T; Sohier P; Poirot B; Haffner A; Carlotti A; Balme B; Castillo C; Jullie ML; Osio A; Lehmann-Che J; Frouin E; Battistella M
    Am J Surg Pathol; 2021 Sep; 45(9):1221-1227. PubMed ID: 33739783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BerEP4 is widely expressed in tumors of the sweat apparatus: a source of potential diagnostic error.
    Afshar M; Deroide F; Robson A
    J Cutan Pathol; 2013 Feb; 40(2):259-64. PubMed ID: 23194306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of YAP1 and NUTM1 rearranged porocarcinoma with corresponding immunohistochemical expression: Review of recent advances in poroma and porocarcinoma pathogenesis with potential diagnostic utility.
    Parra O; Kerr DA; Bridge JA; Loehrer AP; Linos K
    J Cutan Pathol; 2021 Jan; 48(1):95-101. PubMed ID: 32757412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung.
    Chang A; Amin A; Gabrielson E; Illei P; Roden RB; Sharma R; Epstein JI
    Am J Surg Pathol; 2012 Oct; 36(10):1472-6. PubMed ID: 22982890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perilipin and adipophilin expression in sebaceous carcinoma and mimics.
    Boussahmain C; Mochel MC; Hoang MP
    Hum Pathol; 2013 Sep; 44(9):1811-6. PubMed ID: 23642680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Porocarcinoma with YAP1-NUTM1 fusion presenting as a NUT immunohistochemistry-positive lymph node metastasis.
    Christensen DJ; Tuluc M
    J Cutan Pathol; 2023 May; 50(5):410-414. PubMed ID: 36794976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CK7 expression in primary cutaneous squamous cell carcinoma.
    Pulitzer M; Desman G; Busam KJ
    J Cutan Pathol; 2010 Sep; 37(9):966-72. PubMed ID: 20528966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of eccrine porocarcinoma: A treacherous mimic and diagnostic challenge.
    Das D; Datta C; Chatterjee U; De A
    Indian J Pathol Microbiol; 2021; 64(1):186-188. PubMed ID: 33433439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular analysis of NUT-positive poromas and porocarcinomas identifies novel break points of YAP1::NUTM1 fusions.
    Snow JT; Georgantzoglou N; Green DC; Parra O; LeBlanc RE; Yan S; Sriharan A; Momtahen S; Winnick KN; Dimonitsas E; Stavrianos S; Lakiotaki E; Korkolopoulou P; Revelos K; Guo R; Linos K
    J Cutan Pathol; 2022 Oct; 49(10):850-858. PubMed ID: 35665951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct regulations driving YAP1 expression loss in poroma, porocarcinoma and RB1-deficient skin carcinoma.
    Kervarrec T; Frouin E; Collin C; Tallet A; Tallegas M; Pissaloux D; Tirode F; Guyétant S; Samimi M; Gaboriaud P; Touzé A; Schrama D; Houben R; Tabareau-Delalande F; Neuhart A; de la Fouchardière A; Osio A; Cavelier-Balloy B; Laurent-Roussel S; Sohier P; Cyprien T; Balme B; Belzung F; Jullie ML; Cribier B; Battistella M; Macagno N
    Histopathology; 2023 May; 82(6):885-898. PubMed ID: 36720791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Porocarcinoma: an exceedingly rare tumor or a tumor eclipse phenomenon?
    Urso C
    Hum Pathol; 2013 Mar; 44(3):448-9. PubMed ID: 23332868
    [No Abstract]   [Full Text] [Related]  

  • 17. Seborrheic Keratosis With Malignant Transformation (Invasive or Noninvasive Squamous Cell Carcinoma Arising in Seborrheic Keratosis): A Clinicopathologic and Immunohistochemical Study of 11 Cases.
    Goto K; Ogawa K; Hishima T; Oishi N; Tomita O; Tsuyuki T; Oda T; Iwahashi Y; Inaba Y; Honma K
    Am J Dermatopathol; 2022 Dec; 44(12):891-899. PubMed ID: 36395445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Porocarcinoma: an exceedingly rare tumor or a tumor eclipse phenomenon?--Reply.
    Mahalingam M; Hoang MP
    Hum Pathol; 2013 Mar; 44(3):449. PubMed ID: 23290010
    [No Abstract]   [Full Text] [Related]  

  • 19. Aberrant expression of p16 and RB protein in eccrine porocarcinoma.
    Gu LH; Ichiki Y; Kitajima Y
    J Cutan Pathol; 2002 Sep; 29(8):473-9. PubMed ID: 12207741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma.
    Sekine S; Kiyono T; Ryo E; Ogawa R; Wakai S; Ichikawa H; Suzuki K; Arai S; Tsuta K; Ishida M; Sasajima Y; Goshima N; Yamazaki N; Mori T
    J Clin Invest; 2019 May; 129(9):3827-3832. PubMed ID: 31145701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.